yahoo_financeOriginal article
AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success
Phase 2negativeNegative
AI Analysis
Summary
AstraZeneca has terminated its Phase 2 study of a bispecific antibody in non-small cell lung cancer due to unlikely probability of success. The company ended the trial based on futility assessment.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Study ended due to unlikely success
Importance:6/10
Sentiment:
-0.80
clinical_trialstudy_terminationbispecific_antibodyoncologynegative_outcome
Related Companies
Read the original article
Published by yahoo_finance on August 18, 2026 3:59 PM